| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-48308SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-94158SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-49674SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-87679-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-128SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-41487SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-19167SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-360SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22114SS | |||
| Azide and BSA Free | NBP2-80827 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
![Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Human primary cells stained with Mre11 antibody at a dilution of 1:60. cells were fixed in 1:1 Acetone/Methanol. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Immunohistochemistry-NB100-473-img0008.jpg "Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Human primary cells stained with Mre11 antibody at a dilution of 1:60. cells were fixed in 1:1 Acetone/Methanol. ICC/IF image submitted by a verified customer review.")
![<b>Genetic Strategies Validation. </b>Western Blot: Mre11 Antibody (12D7) [NB100-473] - Non-transfected (-) and transfected (+) HeLa whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with Mre11 antibody [12D7] diluted at 1:500. HRP-conjugated anti-mouse IgG antibody (NBP2-19382) was used to detect the primary antibody. A band appears at the theoretical molecular weight of 80 kDa.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Western-Blot-NB100-473-img0010.jpg)
![Western Blot: Mre11 Antibody (12D7) [NB100-473] - Mre11 antibody [12D7] detects Mre11 protein by western blot analysis. A. 30 ug 293T whole cell extract. B. 30 ug whole cell extract of human Mre11-transfected 293T cells. 7.5% SDS-PAGE. Mre11 antibody [12D7] (NB100-473). HRP-conjugated anti-mouse IgG antibody was used to detect the primary antibody. Bands are prominent at the theoretical molecular weight of 80 kDa.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Western-Blot-NB100-473-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Analysis of Mre11 antibody (12D7) on lymphoblastoid cells. Dilution 1:200. Image from verified customer review.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Immunocytochemistry-Immunofluorescence-NB100-473-img0021.jpg)
![Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Mre11 antibody [12D7] detects Mre11 protein at nucleus by immunofluorescent analysis. Sample: HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: Mre11 stained by Mre11 antibody [12D7] (NB100-473).Blue: Hoechst 33342 staining.Scale bar= 10 um.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Immunocytochemistry-Immunofluorescence-NB100-473-img0015.jpg)
![Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Mouse fibroblasts stained with Mre11 Antibody (12D7). ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Immunocytochemistry-Immunofluorescence-NB100-473-img0020.jpg)
![Western Blot: Mre11 Antibody (12D7) [NB100-473] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with Mre11 antibody [12D7] (NB100-473) diluted at 1:500. The HRP-conjugated anti-mouset IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nb100-473_mouse-monoclonal-mre11-antibody-12d7-91020242091437.jpg)
![Western Blot: PKM2 Antibody - BSA Free [NBP1-48308] - Expression profile of PKM isoforms in tissues from mouse organs. PKM1 and PKM2 were detected by Western blotting in under the same experimental conditions at the same time. The full-length blots are presented in Supplementary Figure S2b. Results are presented as the mean +/- SD (** P < 0.01). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep08647) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PKM2-Antibody---BSA-Free-Western-Blot-NBP1-48308-img0018.jpg "Western Blot: PKM2 Antibody - BSA Free [NBP1-48308] - Expression profile of PKM isoforms in tissues from mouse organs. PKM1 and PKM2 were detected by Western blotting in under the same experimental conditions at the same time. The full-length blots are presented in Supplementary Figure S2b. Results are presented as the mean +/- SD (** P < 0.01). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep08647) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: PKM2 Antibody - BSA Free [NBP1-48308] - Analysis of PKM2 in frozen sections of rat glioblastoma tissue. Image courtsey of anonymous customer review.](http://images.novusbio.com/fullsize/PKM2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-48308-img0007.jpg)
![Immunohistochemistry: PKM2 Antibody - BSA Free [NBP1-48308] - Staining of PKM2 in mouse liver tissue.](http://images.novusbio.com/fullsize/PKM2-Antibody---BSA-Free-Immunohistochemistry-NBP1-48308-img0009.jpg)
![Flow Cytometry: PKM2 Antibody - BSA Free [NBP1-48308] - An intracellular stain was performed on Neuro2a cells with PKM2 Antibody NBP1-48308AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/PKM2-Antibody---BSA-Free-Flow-Cytometry-NBP1-48308-img0019.jpg)
![Western Blot: PKM2 Antibody - BSA Free [NBP1-48308] - Analysis of HeLa lysates using NBP1-48308. Image courtesy of Gregg Semenza, (PMID: 21620138).](http://images.novusbio.com/fullsize/PKM2-Antibody---BSA-Free-Western-Blot-NBP1-48308-img0010.jpg)
![Western Blot: PKM2 Antibody - BSA Free [NBP1-48308] - Analysis of PKM2 in MCF7 whole cell lysates.](http://images.novusbio.com/fullsize/PKM2-Antibody---BSA-Free-Western-Blot-NBP1-48308-img0012.jpg)
![Western Blot: PKM2 Antibody - BSA Free [NBP1-48308] - Expression of PKM1 and PKM2 in clinical colorectal cancer samples. The protein expression of PKM1 and PKM2 in clinical specimens of cancer tumor (T) and the adjacent normal tissues (N) is shown. PKM1 and PKM2 were detected by Western blotting in under the same experimental conditions at the same time. The full-length blots are presented in Supplementary Figure S3b. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep08647) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PKM2-Antibody---BSA-Free-Western-Blot-NBP1-48308-img0016.jpg)
![Western Blot: PKM2 Antibody - BSA Free [NBP1-48308] - Expression profile of PKM isoforms in various cancer cell lines, control cell lines, and cells in primary culture. PKM1 and PKM2 were detected by Western blotting under the same experimental conditions at the same time. The full-length blots are presented in Supplementary Figure S2a. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep08647) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PKM2-Antibody---BSA-Free-Western-Blot-NBP1-48308-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: PKM2 Antibody - BSA Free [NBP1-48308] - Analysis of PKM2 in HeLa cells.](http://images.novusbio.com/fullsize/PKM2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-48308-img0008.jpg)
![Immunohistochemistry: PKM2 Antibody - BSA Free [NBP1-48308] - Immunohistochemical staining of normal colon tissue adjacent to tumor tissue of case 10. Results of staining with anti-PKM2 is shown. The boxed regions are enlarged in the images below. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25721733/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PKM2 Antibody - BSA Free-Immunohistochemistry-NBP1-48308-img0020.jpg)
![Flow Cytometry: PKM2 Antibody - BSA Free [NBP1-48308] - An intracellular stain was performed on HeLa cells with PKM2 Antibody NBP1-48308AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/PKM2-Antibody---BSA-Free-Flow-Cytometry-NBP1-48308-img0014.jpg)
![Simple Western: PKM2 Antibody - BSA Free [NBP1-48308] - Lane view shows a specific band for PKM2 in 0.1 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230kDa separation system. * Non-specific interaction with the 230 kDa Simple Western standard may be seen with this antibody.](http://images.novusbio.com/fullsize/PKM2-Antibody---BSA-Free-Simple-Western-NBP1-48308-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: MAT2A Antibody [NB110-94158] - HepG2 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-MAT2A Antibody (NB110-94158) at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/MAT2A-Antibody-Immunocytochemistry-Immunofluorescence-NB110-94158-img0010.jpg "Immunocytochemistry/Immunofluorescence: MAT2A Antibody [NB110-94158] - HepG2 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-MAT2A Antibody (NB110-94158) at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Immunocytochemistry/Immunofluorescence: MAT2A Antibody [NB110-94158] - NIH3T3 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-MAT2A Antibody (NB110-94158) at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/MAT2A-Antibody-Immunocytochemistry-Immunofluorescence-NB110-94158-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: MAT2A Antibody [NB110-94158] - PC12 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-MAT2A Antibody (NB110-94158) at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/MAT2A-Antibody-Immunocytochemistry-Immunofluorescence-NB110-94158-img0012.jpg)
![Western Blot: MAT2A Antibody [NB110-94158] - Loss of PKM2 impairs methylation capacity, reduces DNA methylation and leads to the expression of endogenous retroviral elements. Western blot analysis of MAT2A, P53, P21 and PKM2 in control, P53KD, PKM2KD and PKM2KD/P53KD ECs. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-018-06406-8), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/MAT2A-Antibody-Western-Blot-NB110-94158-img0008.jpg)
![Immunohistochemistry-Paraffin: MAT2A Antibody [NB110-94158] - Analysis of a FFPE tissue section of human kidney using 1:200 dilution of MAT2A antibody (NB110-94158). The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/MAT2A-Antibody-Immunohistochemistry-Paraffin-NB110-94158-img0009.jpg)
![Western Blot: MAT2A Antibody [NB110-94158] - Total protein from HeLa and HepG2 cells and Human and Mouse Kidney was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-MAT2A in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/MAT2A-Antibody-Western-Blot-NB110-94158-img0005.jpg)
![Western Blot: MAT2A Antibody [NB110-94158] - Detection of MAT2A in HepG2 whole cell lysates.](http://images.novusbio.com/fullsize/MAT2A-Antibody-Western-Blot-NB110-94158-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: MAT2A Antibody [NB110-94158] - MAT2A antibody was tested in HepG2 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/MAT2A-Antibody-Immunocytochemistry-Immunofluorescence-NB110-94158-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: MAT2A Antibody [NB110-94158] - Mouse embryonic stem cells (mESCs) were fixed with paraformaldehyde, permeabilized with Triton, blocked with 4% BSA and 1% normal goat serum, and incubated with 1:200 dilution of MAT2A antibody. Then, samples were stained with anti-rabbit Alexa Fluor 594 (1:1000) and NucBlue. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/MAT2A-Antibody-Immunocytochemistry-Immunofluorescence-NB110-94158-img0006.jpg)
![Simple Western: MAT2A Antibody [NB110-94158] - Human HepG2 cell lysate (0.2 ug/uL total protein). Antibody at 1:250. Simple Western image submitted by a verified customer review.](http://images.novusbio.com/fullsize/MAT2A-Antibody-Simple-Western-NB110-94158-img0007.jpg)
![Western Blot: DEPTOR/DEPDC6 Antibody - BSA Free [NBP1-49674] - PA regulates adipogenic differentiation by displacing DEPTOR from mTORC1. 3T3-L1 preadipocytes were transfected with a PPRE luciferase reporter plasmid vector, induced to differentiate for 3 h, and then luciferase activity was measured. 3T3-L1 cells were differentiated in the absence or presence of 300 uM C8-PA. Cell lysates and immunoprecipitates against raptor were analyzed by western blotting. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep36968), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/DEPTOR-DEPDC6-Antibody---BSA-Free-Western-Blot-NBP1-49674-img0012.jpg "Western Blot: DEPTOR/DEPDC6 Antibody - BSA Free [NBP1-49674] - PA regulates adipogenic differentiation by displacing DEPTOR from mTORC1. 3T3-L1 preadipocytes were transfected with a PPRE luciferase reporter plasmid vector, induced to differentiate for 3 h, and then luciferase activity was measured. 3T3-L1 cells were differentiated in the absence or presence of 300 uM C8-PA. Cell lysates and immunoprecipitates against raptor were analyzed by western blotting. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep36968), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: DEPTOR/DEPDC6 Antibody - BSA Free [NBP1-49674] - Antibody was tested in MCF7 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/DEPTOR-DEPDC6-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-49674-img0011.jpg)
![Immunohistochemistry: DEPTOR/DEPDC6 Antibody - BSA Free [NBP1-49674] - Staining of DEPTOR in mouse spleen using DAB with a hematoxylin counterstain.](http://images.novusbio.com/fullsize/DEPTOR-DEPDC6-Antibody---BSA-Free-Immunohistochemistry-NBP1-49674-img0009.jpg)
![Western Blot: DEPTOR/DEPDC6 Antibody - BSA Free [NBP1-49674] - Analysis of DEPDC6 in (A) human liver and (B) mouse liver.](http://images.novusbio.com/fullsize/DEPTOR-DEPDC6-Antibody---BSA-Free-Western-Blot-NBP1-49674-img0010.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: DEPTOR/DEPDC6 Antibody - BSA Free [NBP1-49674] - Whole-body DEPTOR null mice are viable, fertile, normal in size, and do not display any gross physical abnormalities. Western blot showing the expression of DEPTOR/DEPDC6 in tissues of Deptor wild-type (wt/wt), heterozygote (Delta/wt) or knockout (Delta/Delta) mice. Akt was used as a loading control. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28462079/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/DEPTOR-DEPDC6 Antibody - BSA Free-Knockout Validated-NBP1-49674-img0013.jpg)
![Immunohistochemistry-Paraffin: Aquaporin-4 Antibody [NBP1-87679] - Analysis in human cerebral cortex and liver tissues. Corresponding AQP4 RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/Aquaporin-4-Antibody-Immunohistochemistry-Paraffin-NBP1-87679-img0027.jpg "<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: Aquaporin-4 Antibody [NBP1-87679] - Analysis in human cerebral cortex and liver tissues. Corresponding AQP4 RNA-seq data are presented for the same tissues.")
![<b>Orthogonal Strategies Validation. </b>Western Blot: Aquaporin-4 Antibody [NBP1-87679] - Analysis in human brain tissue.](http://images.novusbio.com/fullsize/Aquaporin-4-Antibody-Western-Blot-NBP1-87679-img0017.jpg)
![Immunohistochemistry: Aquaporin-4 Antibody [NBP1-87679] - Staining of mouse cerebellum shows positivity in astrocytes, mainly in the molecular layer.](http://images.novusbio.com/fullsize/Aquaporin-4-Antibody-Immunohistochemistry-Paraffin-NBP1-87679-img0029.jpg)
![Immunohistochemistry-Paraffin: Aquaporin-4 Antibody [NBP1-87679] - Staining of human cerebellum shows moderate to strong membranous positivity in astrocytes, mainly in the molecular layer.](http://images.novusbio.com/fullsize/Aquaporin-4-Antibody-Immunohistochemistry-Paraffin-NBP1-87679-img0030.jpg)
![Immunohistochemistry-Paraffin: Aquaporin-4 Antibody [NBP1-87679] - Staining of human cerebral cortex shows moderate to strong membranous positivity in astrocytes.](http://images.novusbio.com/fullsize/Aquaporin-4-Antibody-Immunohistochemistry-Paraffin-NBP1-87679-img0031.jpg)
![Immunohistochemistry-Paraffin: Aquaporin-4 Antibody [NBP1-87679] - Staining of human liver shows no positivity in hepatocytes, as expected.](http://images.novusbio.com/fullsize/Aquaporin-4-Antibody-Immunohistochemistry-Paraffin-NBP1-87679-img0032.jpg)
![Immunohistochemistry-Paraffin: Aquaporin-4 Antibody [NBP1-87679] - Staining of human stomach shows strong membranous positivity in glandular cells.](http://images.novusbio.com/fullsize/Aquaporin-4-Antibody-Immunohistochemistry-Paraffin-NBP1-87679-img0033.jpg)
![Immunohistochemistry-Frozen: Aquaporin-4 Antibody [NBP1-87679] - Mouse trigeminal ganglion stained with Aquaporin-4 antibody at 1:5000. Image submitted by a verified customer review](http://images.novusbio.com/fullsize/Aquaporin-4-Antibody-Immunohistochemistry-Frozen-NBP1-87679-img0036.jpg)
![Induction of atrogin 1 mRNA and protein expression by rotator cuff tear (RCT). (a) Expression of transcripts encoding the E3 ubiquitin-protein ligases atrogin 1, MuRF1, and UBR2 in injured muscle after RCT (n = 12 per group). (b) Atrogin 1 protein expression in muscle isolated at different stages after RCT (n = 7 per group). Densitometric analyses of the western blots are shown on the right. Data represent means +/- standard errors of the means. *P < 0.05. (c) Immunofluorescence (IF) microscopy analyses of muscle isolated at different stages after RCT. The red signal represents atrogin 1 protein. The negative control (secondary antibody only) for the IF showed no specific signal (data not shown). (d) Loss of AQP4 protein by overexpression of atrogin 1. C2C12 cells were treated with an adenovirus expressing atrogin 1 [Ad-atrogin 1; multiplicity of infection (MOI) = 50, 100, 200] for 48 h, and western blot analysis was performed with each designated antibody. (e) Monomeric ubiquitin protein expression in muscle cells isolated at different stages after RCT. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32843684), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-87679_rabbit-polyclonal-aquaporin-4-antibody-western-blot-13220261319313.jpg)
![Increased levels of HMGB1 protein in muscle injured by rotator cuff tear (RCT). (a) Expression level of HMGB1 protein in muscle isolated at different stages after RCT (n = 7 per group). Densitometric analyses of the western blots are shown on the right. Data represent means +/- standard errors of the means. *P < 0.05. (b) Immunofluorescence (IF) microscopy analyses of muscle cells isolated at different stages after RCT. The green signal represents HMGB1 protein. The negative control (secondary antibody only) for the IF showed no specific signal (data not shown). (c) Expression of atrogin 1 mRNA in C2C12 myotubes treated with 200 ng/mL recombinant mouse HMGB1 for the indicated time periods. (d) Atrogin 1, ubiquitin, and AQP4 protein levels in C2C12 myotubes treated with 200 ng/mL HMGB1 and an adenovirus expressing atrogin 1 [Ad-atrogin 1; multiplicity of infection (MOI) = 100] for 48 h. (e) Ubiquitination of AQP4 caused by HMGB1 and atrogin 1. C2C12 myotubes were treated with 200 ng/mL HMGB1 and Ad-atrogin 1 (MOI = 100) with or without MG132. After 48 h of incubation, cell lysates were prepared for a ubiquitination assay using anti-AQP4 and anti-ubiquitin antibodies. (f) Expression of atrogin 1 mRNA in C2C12 myotubes exposed to 5 μM SB203580 (a p38 MAPK inhibitor), LY294002 (a PI3K inhibitor), BAY 11-7082 (an NF-kappa B inhibitor), PD98059 (an MEK inhibitor), or SP600125 (a JNK inhibitor). Cells were exposed to each inhibitor for 1 h prior to treatment with 200 ng/mL HMGB1 for 24 h. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32843684), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-87679_rabbit-polyclonal-aquaporin-4-antibody-western-blot-132202613153820.jpg)
![Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-128] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti AHR [NB100-128] at a 1:100 dilution overnight at 4C and detected with an anti-goat DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-128-img0004.jpg "Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-128] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti AHR [NB100-128] at a 1:100 dilution overnight at 4C and detected with an anti-goat DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.")
![Immunohistochemistry-Paraffin: AHR Antibody [NB100-128] - Analysis of FFPE human liver using 1:200 conc. of AHR antibody on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunohistochemistry-Paraffin-NB100-128-img0006.jpg)
![Gel Super Shift Assays: AHR Antibody [NB100-128] - EMSA validation of AHR antibody on U937 cells nuclear protein. Image submitted by verified customer - see review for protocol details.](http://images.novusbio.com/fullsize/AHR-Antibody-Gel-Super-Shift-Assays-NB100-128-img0003.jpg)
![Western Blot: DGAT1 Antibody [NB110-41487] - Detection of DGAT1 in HepG2 lysate.](http://images.novusbio.com/fullsize/DGAT1-Antibody-Western-Blot-NB110-41487-img0002.jpg "Western Blot: DGAT1 Antibody [NB110-41487] - Detection of DGAT1 in HepG2 lysate.")
![Immunocytochemistry/Immunofluorescence: DGAT1 Antibody [NB110-41487] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-DGAT1 at 5 ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/DGAT1-Antibody-Immunocytochemistry-Immunofluorescence-NB110-41487-img0003.jpg)
![Western Blot: DGAT1 Antibody [NB110-41487] - Factors regulating lipid storage and breakdown in C2C12 muscle cells.Muscle cells were incubated with PALM (open), NORM (filled), or HSFA (hatched). Pictured is protein abundance of DGAT1. In the figure panel, the data is expressed relative to a no fatty acid control condition (0mM). In panel B, #P<0.05 for a main effect of HSFA vs. PALM and NORM. Representative blot shown inset above the figure panel. DGAT = diacylglycerol acyltransferase; AU = arbitrary units. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0120871), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/DGAT1-Antibody-Western-Blot-NB110-41487-img0004.jpg)
![Western Blot: LC3A Antibody [NBP1-19167] - Total protein from HeLa and Neuro2A cells treated with or without 50 uM chloroquine for 24 hours was separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-LC3A in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the detection LC3 II upon chloroquine treatment.](http://images.novusbio.com/fullsize/LC3A-Antibody-Western-Blot-NBP1-19167-img0012.jpg "<b>Biological Strategies Validation. </b>Western Blot: LC3A Antibody [NBP1-19167] - Total protein from HeLa and Neuro2A cells treated with or without 50 uM chloroquine for 24 hours was separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-LC3A in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the detection LC3 II upon chloroquine treatment.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: LC3A Antibody [NBP1-19167] - LC3/MAP1 [NBP1-19167] - LC3 antibody was tested in HeLa cells with Dylight 488 (green). Cells were treated overnight with 50 uM chloroquine to induce autophagosome formation. Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/LC3A-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-19167-img0013.jpg)
![Immunohistochemistry-Paraffin: LC3A Antibody [NBP1-19167] - Analysis of a FFPE tissue section of mouse brain using LC3 antibody at 1:300 dilution. The signal was developed using HRP-labelled secondary antibody and DAB reagent, and the sections/nuclei were further counterstained with hematoxylin. Note the diffused cytoplasmic staining of LC3 in all of the cells with highest positivity in various neurons.](http://images.novusbio.com/fullsize/LC3A-Antibody-Immunohistochemistry-Paraffin-NBP1-19167-img0014.jpg)
![Western Blot: LC3/MAP1LC3A Antibody [NBP1-19167] - Human brain lysate.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Western-Blot-NBP1-19167-img0004.jpg)
![Immunohistochemistry-Paraffin: LC3A Antibody [NBP1-19167] - Analysis of a FFPE tissue section of mouse liver using LC3 antibody at 1:300 dilution. The signal was developed using HRP-labelled secondary antibody and DAB reagent, and the sections/nuclei were further counterstained with hematoxylin. Note the diffused cytoplasmic staining of LC3 in all of the hepatocytes and other liver cells.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Immunohistochemistry-Paraffin-NBP1-19167-img0010.jpg)
![Simple Western: LC3A Antibody [NBP1-19167] - Image shows a specific band for LC3 in 0.5 mg/mL of Neuro2A lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Simple-Western-NBP1-19167-img0009.jpg)
![Western Blot: ATP7b Antibody [NB100-360] - ATP7b detected in 20 ug of mouse brain membrane fraction.](http://images.novusbio.com/fullsize/ATP7b-Antibody-Western-Blot-NB100-360-img0003.jpg "Western Blot: ATP7b Antibody [NB100-360] - ATP7b detected in 20 ug of mouse brain membrane fraction.")
![Immunocytochemistry/Immunofluorescence: ATP7b Antibody [NB100-360] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-ATP7b [NB100-360] at a 1:100 dilution overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse DyLight 550 (Red) at 1:500. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/ATP7b-Antibody-Immunocytochemistry-Immunofluorescence-NB100-360-img0005.jpg)
![Immunohistochemistry: ATP7b Antibody [NB100-360] - Analysis of ATP7b in mouse liver using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/ATP7b-Antibody-Immunohistochemistry-NB100-360-img0004.jpg)
![Western Blot: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Western blot analysis using TGF beta 1 mAb against human LAP (TGF-beta 1) recombinant protein. (Expected MW is 41 kDa)](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Western-Blot-NBP2-22114-img0002.jpg "Western Blot: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Western blot analysis using TGF beta 1 mAb against human LAP (TGF-beta 1) recombinant protein. (Expected MW is 41 kDa)")
![Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Immunohistochemical analysis of paraffin-embedded lymphoid tissue tissues using LAP (TGF-beta 1) mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Immunohistochemistry-Paraffin-NBP2-22114-img0005.jpg)
![Flow Cytometry: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Flow cytometric analysis of A549 cells using LAP (TGF-beta 1) mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Flow-Cytometry-NBP2-22114-img0003.jpg)
![Western Blot: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Western blot analysis of human stomach tissue (A) and human small intestine tissue (B) using TGF beta 1 antibody (NBP2-22114) at 2 ug/ml.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Western-Blot-NBP2-22114-img0007.jpg)
![Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Human tonsil. Image from verified customer review.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Immunohistochemistry-Paraffin-NBP2-22114-img0006.jpg)
![Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Immunohistochemical analysis of paraffin-embedded lung cancer tissues using LAP (TGF-beta 1) mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Immunohistochemistry-Paraffin-NBP2-22114-img0004.jpg)
![ELISA: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng).](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-ELISA-NBP2-22114-img0001.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Western Blot: DDX6 Antibody [NB200-192] - Detection of Human and Mouse DDX6 by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa, 293T, and mouse NIH3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-DDX6 antibody NB200-192 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 1 second.](http://images.novusbio.com/fullsize/DDX6-Antibody-Western-Blot-NB200-192-img0009.jpg "Western Blot: DDX6 Antibody [NB200-192] - Detection of Human and Mouse DDX6 by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa, 293T, and mouse NIH3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-DDX6 antibody NB200-192 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 1 second.")
![Immunohistochemistry-Paraffin: DDX6 Antibody [NB200-192] - FFPE section of human colon carcinoma. Antibody: Affinity purified rabbit anti-DDX6 (left) and Lot 3 (right) used at a dilution of 1:1,000 (1ug/ml). Detection: DAB. Counterstain: IHC Hematoxylin (blue).](http://images.novusbio.com/fullsize/DDX6-Antibody-Immunohistochemistry-Paraffin-NB200-192-img0008.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: DDX6 Antibody [NB200-192] - Detection of human DDX6 by western blot of immunoprecipitates. Samples: Whole cell lysate (0.5 or 1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-DDX6 antibody NB200-192 (lot NB200-192-3) used for IP at 6 ug per reaction. DDX6 was also immunoprecipitated by a previous lot of this antibody (NB200-192-2) and rabbit anti-DDX6 antibody NB200-191. For blotting immunoprecipitated DDX6, NB200-192 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 1 second.](http://images.novusbio.com/fullsize/DDX6-Antibody-Immunoprecipitation-NB200-192-img0010.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: DDX6 Antibody [NB200-192] - Western blot analysis of HNRNPK and DDX6 protein levels upon HNRNPK or DDX6 knockdown. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-019-12238-x), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/DDX6-Antibody-Knockdown-Validated-NB200-192-img0011.jpg)
![Immunocytochemistry/ Immunofluorescence: DDX6 Antibody [NB200-192] - 5-FU-induced SG assembly is rescued by interfering with RNA incorporation. HeLa cells were treated with 1 mM Urd, 0.1 mM 5-FU or both, as well as with 1 μM FUrd or a combination of 1 μM FUrd & 10 μM Urd. Localization of SG marker protein TIAR (green) & SG/P-body marker protein DDX6 (red) was investigated. Nuclei were stained with Hoechst. Scale bars represent 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24728989), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-192_rabbit-polyclonal-ddx6-antibody-310202415363749.jpg)
![Immunocytochemistry/ Immunofluorescence: DDX6 Antibody [NB200-192] - 5-FU-induced SG assembly depends on RNA incorporation. (A) Schematic representation of the cellular 5-FU metabolism leading to incorporation of the different metabolites into RNA or DNA. (B) HeLa cells were treated with two concentrations of the 5-FU metabolites FUrd or FdUrd for 72 h. SG marker protein TIAR (green) & SG/P-body marker protein DDX6 (red) were visualized. Nuclei were stained with Hoechst. Scale bars represent 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24728989), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-192_rabbit-polyclonal-ddx6-antibody-310202415371964.jpg)
![Western Blot: DDX6 Antibody [NB200-192] - HNRNPK is necessary for DDX6 to bind differentiation associated mRNAs. a RNA IP was performed in CTLi & HNRNPKi cells using a DDX6 antibody. RT-QPCR was used to determine the levels of binding between DDX6 & differentiation associated mRNAs in the presence or absence of HNRNPK. IGG IPs in CTLi & HNRNPKi cells were used as specificity controls. Binding was calculated as a percent of input. b RNA IP was performed in CTLi & DDX6i cells using a HNRNPK antibody. RT-QPCR was used to determine the levels of binding between HNRNPK & differentiation associated mRNAs in the presence or absence of DDX6. IGG IPs in CTLi & DDX6i cells were used as specificity controls. n = 4. c Western blot analysis of HNRNPK & DDX6 protein levels upon HNRNPK or DDX6 knockdown. d Immunoprecipitations (IPs) were performed using either an HNRNPK or DDX6 antibody or IGG & Western blotted for HNRNPK or DDX6 protein expression. IPs were performed +/− RNase A. Five percent of the cell lysate was used as input. Representative blots are shown. n = 3 independent experiments performed for Fig. 3 unless otherwise indicated. All error bars = SD. ****p < 0.0001, ***p < 0.001 (2 way ANOVA followed by Tukey’s multiple comparison test for a, b) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31519929), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-192_rabbit-polyclonal-ddx6-antibody-310202416212349.jpg)
![Western Blot: DDX6 Antibody [NB200-192] - HNRNPK is necessary for DDX6 to bind differentiation associated mRNAs. a RNA IP was performed in CTLi & HNRNPKi cells using a DDX6 antibody. RT-QPCR was used to determine the levels of binding between DDX6 & differentiation associated mRNAs in the presence or absence of HNRNPK. IGG IPs in CTLi & HNRNPKi cells were used as specificity controls. Binding was calculated as a percent of input. b RNA IP was performed in CTLi & DDX6i cells using a HNRNPK antibody. RT-QPCR was used to determine the levels of binding between HNRNPK & differentiation associated mRNAs in the presence or absence of DDX6. IGG IPs in CTLi & DDX6i cells were used as specificity controls. n = 4. c Western blot analysis of HNRNPK & DDX6 protein levels upon HNRNPK or DDX6 knockdown. d Immunoprecipitations (IPs) were performed using either an HNRNPK or DDX6 antibody or IGG & Western blotted for HNRNPK or DDX6 protein expression. IPs were performed +/− RNase A. Five percent of the cell lysate was used as input. Representative blots are shown. n = 3 independent experiments performed for Fig. 3 unless otherwise indicated. All error bars = SD. ****p < 0.0001, ***p < 0.001 (2 way ANOVA followed by Tukey’s multiple comparison test for a, b) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31519929), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-192_rabbit-polyclonal-ddx6-antibody-310202416205119.jpg)